Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to educate people with bronchiectasis about how to better manage the disease.

Boehringer Ingelheim has launched Vetmedin (pimobendan) 1.5 mg/ml oral solution for dogs in the UK, offering a new treatment ...

UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...

Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic and progressive lung condition that ...

The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...

Physicians treating patients with Crohn's disease face a plethora of drug choices. Yet, overall rates of clinical response seem stable over time,1 suggesting the existence of a therapeutic ceiling ...

TOKYO -- German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base ...

Boehringer Ingelheim’s Spevigo (spesolimab) has been recommended by the National Institute for Health and Care Excellence ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...